Showing results (281-290 of 329) with videos related to
Sort By:
Pageof 33
International Journal of Cardiology|May 2, 2009
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGYSarah A Spinler, Kenneth W Mahaffey, Dianne Gallup, et al.Journal of the American College of Cardiology|January 4, 2011
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trialClaes Held, Nils Asenblad, Jean Pierre Bassand, et al.European Heart Journal|March 25, 2014
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trialJonathan P Piccini, Jyotsna Garg, Manesh R Patel, et al.Circulation|December 6, 2012
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohortsJonathan P Piccini, Susanna R Stevens, YuChiao Chang, et al.European Heart Journal|October 18, 2013
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trialKenneth W Mahaffey, Susanna R Stevens, Harvey D White, et al.American Heart Journal|February 11, 2021
Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AFVanessa Blumer, Manuel Rivera, Ramón Corbalán, et al.The New England Journal of Medicine|August 12, 2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationManesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, et al.American Heart Journal|July 22, 2020
Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart ValveOliver K Jawitz, Tracy Y Wang, Renato D Lopes, et al.Journal of the American Heart Association|March 10, 2016
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AFSean D Pokorney, Jonathan P Piccini, Susanna R Stevens, et al.American Heart Journal|April 1, 2009
Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registryEric M Crespo, Gustavo B F Oliveira, Emily F Honeycutt, et al.Pageof 33